Sense and Nonsense about Autism: Beyond Genetics
“Autism is currently, in our view, the most important and the fastest-evolving disorder in all of medical science and promises to remain so for the foreseeable future.” —-Dr. Jeffrey A. Lieberman, chairman of the department of psychiatry at Columbia University’s school of medicine.
A few months back David Kirby (author of the book “Evidence of Harm”) interviewed Katy Wright about her autistic child Christian, and more specifically the recovery that he was beginning to make with biomedical treatments that have been developed over the years by the MDs and Ph.D.s involved with the organization Defeat Autism Now (DAN). (http://www.autismmedia.org/media15.html)
Katy makes no bones about what she believes happened to her son: “I believe that Christian’s regression and subsequent autism was the result of receiving six vaccines during one office visit at two months of age,” she wrote. “He screamed for twelve hours and had a 104 degree fever nearly the entire time. His vaccines contained thimerosal,” the mercury-based preservative. “It is devastating,” she added, “because so much of this is preventable.” Continue reading “Sense and Nonsense on Autism: Beyond Genetics”
An article in a recent issue of the New England Journal of Medicine finds that anti-depressants don’t contribute significantly to the recovery of bipolar patients. It is estimated that some 70% of bipolars are also being prescribed one or another anti-depressant. Since these are not fast-acting medications, it is often difficult to tell which of the medications being prescribed are actually doing the work.The surprise in the paper, however, was something else. It turns out that the placebo group did better than the medication group! Not only did the addition of anti-depressants fail to improve outcome, but the outcome was actually somewhat worse overall than among those who did not have anti-depressants added to their regimen. The difference was not statistically significant, according to the researchers. Some 23.5% of the treatment arm made “durable recoveries,” whereas some 27.3% of the placebo group did so.